Prognostic Impact of Copeptin and Mid-Regional
Pro-Adrenomedullin in Chronic Heart Failure with Regard to
Comorbidities

J 2018

Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities

ŠPINAROVÁ, Lenka, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Jindřich ŠPINAR, Jiří PAŘENICA et. al.

Základní údaje

Originální název

Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities

Autoři

ŠPINAROVÁ, Lenka (203 Česká republika, garant, domácí), Monika ŠPINAROVÁ (203 Česká republika, domácí), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Česká republika, domácí), Jindřich ŠPINAR (203 Česká republika, domácí), Jiří PAŘENICA (203 Česká republika, domácí), Ondřej LUDKA (203 Česká republika, domácí), Karel LÁBR (203 Česká republika), F. MALEK (203 Česká republika), P. OSTADAL (203 Česká republika), D. VONDRAKOVA (203 Česká republika), Josef TOMANDL (203 Česká republika, domácí), Jana VEVERKOVÁ (203 Česká republika, domácí), Jolana LIPKOVÁ (203 Česká republika, domácí), Klára BENEŠOVÁ (203 Česká republika, domácí) a Jiří JARKOVSKÝ (203 Česká republika, domácí)

Vydání

Journal of Cardiovascular & Diseases Diagnosis, (Romania), OMICS International, 2018, 2329-9517

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Rumunsko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/18:00103531

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4172/2329-9517.1000326

Klíčová slova anglicky

Chronic heart failure; AHEAD score; Copeptin; Midregional pro-adrenomedullin; Prognosis

Štítky

EL OK, rivok

Změněno: 6. 6. 2019 09:08, Soňa Böhmová

Anotace

V originále

The aim of the study is to evaluate the impact of new humoral substances: copeptin and mid- regional proadrenomedullin (MR-proADM) on one-year survival of patients with stable systolic chronic heart failure (CHF) and to compare them with AHEAD score assessing the comorbidities. The FAR NHL (FARmacology and NeuroHumoraL activation) registry is a database of patients with stable CHF (ejection fraction (EF) <50%) treated in specialized HF departments. AHEAD score is a simple bed-side mortality predictive model based on age and comorbidities. Primary endpoint after 1-year follow-up was: death or hospitalization for decompensation of HF or heart transplantation or LVAD implantation. To whole FAR NHL registry, a total amount of 1088 patients were included, in 552 of them the levels of copeptin and MR-proADM were available. Mean age was 65+12 years, mean EF was 31+9%. Patients without primary endpoint were assigned as group A (469 pts), those with the primary endpoint group B (83 pts). There were statistically significant differences between the groups in the levels of copeptin: group A median 15.9 pmol/l (3.4-50.9) vs group B 23.7 pmol/l(5.0-89.44) (p<0.001), MR-proADM: group A median 0.63 nmol/l(0.32-1.34) vs group B 0.74 nmol/l (0.4-1.94) (p<0.001). Relationship of AHEAD score to primary endpoint in the first year of follow-up was not significant, but within 24th month it reached statistical significance: p= 0.017. Patients with higher AHEAD score (more comorbidities) reached more often the primary end-point.

Citovat

ŠPINAROVÁ, Lenka, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Jindřich ŠPINAR, Jiří PAŘENICA, Ondřej LUDKA, Karel LÁBR, F. MALEK, P. OSTADAL, D. VONDRAKOVA, Josef TOMANDL, Jana VEVERKOVÁ, Jolana LIPKOVÁ, Klára BENEŠOVÁ a Jiří JARKOVSKÝ. Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities. Journal of Cardiovascular & Diseases Diagnosis. (Romania): OMICS International, 2018, roč. 6, č. 4, s. 1-5. ISSN 2329-9517. Dostupné z: https://dx.doi.org/10.4172/2329-9517.1000326.

@article{1430497,
   author = {Špinarová, Lenka and Špinarová, Monika and Pávková Goldbergová, Monika and Špinar, Jindřich and Pařenica, Jiří and Ludka, Ondřej and Lábr, Karel and Malek, F. and Ostadal, P. and Vondrakova, D. and Tomandl, Josef and Veverková, Jana and Lipková, Jolana and Benešová, Klára and Jarkovský, Jiří},
   article_location = {(Romania)},
   article_number = {4},
   doi = {http://dx.doi.org/10.4172/2329-9517.1000326},
   keywords = {Chronic heart failure; AHEAD score; Copeptin; Midregional pro-adrenomedullin; Prognosis},
   language = {eng},
   issn = {2329-9517},
   journal = {Journal of Cardiovascular & Diseases Diagnosis},
   title = {Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities},
   volume = {6},
   year = {2018}
}

TY  - JOUR
ID  - 1430497
AU  - Špinarová, Lenka - Špinarová, Monika - Pávková Goldbergová, Monika - Špinar, Jindřich - Pařenica, Jiří - Ludka, Ondřej - Lábr, Karel - Malek, F. - Ostadal, P. - Vondrakova, D. - Tomandl, Josef - Veverková, Jana - Lipková, Jolana - Benešová, Klára - Jarkovský, Jiří
PY  - 2018
TI  - Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities
JF  - Journal of Cardiovascular & Diseases Diagnosis
VL  - 6
IS  - 4
SP  - 1-5
EP  - 1-5
PB  - OMICS International
SN  - 23299517
KW  - Chronic heart failure
KW  - AHEAD score
KW  - Copeptin
KW  - Midregional pro-adrenomedullin
KW  - Prognosis
N2  - The aim of the study is to evaluate the impact of new humoral substances: copeptin and mid- regional proadrenomedullin (MR-proADM) on one-year survival of patients with stable systolic chronic heart failure (CHF) and to compare them with AHEAD score assessing the comorbidities. The FAR NHL (FARmacology and NeuroHumoraL activation) registry is a database of patients with stable CHF (ejection fraction (EF) <50%) treated in specialized HF departments. AHEAD score is a simple bed-side mortality predictive model based on age and comorbidities. Primary endpoint after 1-year follow-up was: death or hospitalization for decompensation of HF or heart transplantation or LVAD implantation. To whole FAR NHL registry, a total amount of 1088 patients were included, in 552 of them the levels of copeptin and MR-proADM were available. Mean age was 65+12 years, mean EF was 31+9%. Patients without primary endpoint were assigned as group A (469 pts), those with the primary endpoint group B (83 pts). There were statistically significant differences between the groups in the levels of copeptin: group A median 15.9 pmol/l (3.4-50.9) vs group B 23.7 pmol/l(5.0-89.44) (p<0.001), MR-proADM: group A median 0.63 nmol/l(0.32-1.34) vs group B 0.74 nmol/l (0.4-1.94) (p<0.001). Relationship of AHEAD score to primary endpoint in the first year of follow-up was not significant, but within 24th month it reached statistical significance: p= 0.017. Patients with higher AHEAD score (more comorbidities) reached more often the primary end-point.
ER  -

ŠPINAROVÁ, Lenka, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Jindřich ŠPINAR, Jiří PAŘENICA, Ondřej LUDKA, Karel LÁBR, F. MALEK, P. OSTADAL, D. VONDRAKOVA, Josef TOMANDL, Jana VEVERKOVÁ, Jolana LIPKOVÁ, Klára BENEŠOVÁ a Jiří JARKOVSKÝ. Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities. \textit{Journal of Cardiovascular \&{} Diseases Diagnosis}. (Romania): OMICS International, 2018, roč.~6, č.~4, s.~1-5. ISSN~2329-9517. Dostupné z: https://dx.doi.org/10.4172/2329-9517.1000326.

Podrobný výpis o publikaci